

Bristol-Myers Squibb **Devens, Massachusetts, Facility**

Bristol-Myers Squibb is currently constructing a new large-scale multi-product bulk biologics in Devens, Massachusetts. The construction of the Devens facility represents a critical component in Bristol-Myers Squibb's transformation toward a leading BioPharma company.

Facts about Devens

- Former U.S Army base
- Brownfield project - redevelopment
- Approximately 40 miles northwest of Boston
- Proximity to biotech cluster

The Site

- 5 year project (groundbreaking to commercial operation)
- \$750 million investment, the largest capital investment in BMS's history
- Devens will be devoted to biologics manufacturing and will initially satisfy production requirements for *Orencia*, the company's biologic therapy for rheumatoid arthritis
- Flexible, modular construction: Module one is currently under construction; master plan allows for up to three modules
- 6 x 20,000 liter production bioreactors
- One purification train
- When completed, site will include a warehouse, central utilities building, water pre-treatment, technical services, manufacturing, analytical and quality laboratories as well as administrative offices
- Approximately 350 employees upon completion of phase 1 of construction in 2011
- FDA approved in 2012
- Designed to comply with U.S. and EU requirements
- LEEDS certification – BMS expects Devens to be the first biologics manufacturing facility to receive LEEDS certification in the U.S.